Adverum Reports First Quarter 2021 Results
06 mai 2021 16h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
01 mai 2021 15h26 HE
|
Adverum Biotechnologies, Inc.
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose -- ...
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
28 avr. 2021 16h01 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony...
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
22 avr. 2021 16h15 HE
|
Adverum Biotechnologies, Inc.
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. ...
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
21 avr. 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Stockholders to Vote the WHITE Proxy...
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
16 avr. 2021 08h05 HE
|
Adverum Biotechnologies, Inc.
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),...
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
15 avr. 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
Urges Stockholders to Vote the WHITE Proxy Card “FOR ALL” of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. Annual...
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
30 mars 2021 09h00 HE
|
Adverum Biotechnologies, Inc.
-- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead -- REDWOOD CITY,...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 mars 2021 16h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
17 mars 2021 17h10 HE
|
Adverum Biotechnologies, Inc.
Responds to Intent to Nominate Directors from Sonic Fund Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders REDWOOD CITY, Calif., March 17,...